2013-03-21 17:28:55 -
ORION CORPORATION STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25
Orion Corporation has submitted a marketing authorisation application for
combined budesonide-formoterol formulation of the Easyhaler® product family in
Europe. Orion applies for approval in European Union through decentralised
procedure. The review process will commence once all involved member states have
validated the application.
Timo Lappalainen Reijo Salonen
President and CEO SVP, Research and Development
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company
is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE